Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Decrease in Short Interest
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Decrease in Short Interest
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) was the target of a significant decline in short interest in September. As of September 15th, there was short interest totalling 471,600 shares, a decline of 58.6% from the August 31st total of 1,140,000 shares. Currently, 6.5% of the company's stock are short sold. Based on an average trading volume of 11,830,000 shares, the days-to-cover ratio is presently 0.0 days.
光明之心生物科学公司(纳斯达克：毒品获得评级)是空头股数9月份大幅下跌的目标。截至9月15日，空头股数共有47.16万股，较8月31日的114万股下降了58.6%。目前，该公司6.5%的股票被卖空。以11,830,000股的平均成交量计算，目前的天数与回补比率为0.0天。
Bright Minds Biosciences Trading Down 1.5 %
Bright Minds生物科学公司股价下跌1.5%
Bright Minds Biosciences stock traded down $0.02 during mid-day trading on Wednesday, hitting $1.28. The company had a trading volume of 3,300 shares, compared to its average volume of 7,419,385. The stock's 50 day moving average price is $1.42 and its two-hundred day moving average price is $1.22. Bright Minds Biosciences has a 12 month low of $0.75 and a 12 month high of $8.95.
在周三午盘交易中，Bright Minds Biosciences的股价下跌0.02美元，触及1.28美元。该公司成交量为3,300股，而其平均成交量为7,419,385股。该股的50日移动均线价格为1.42美元，200日移动均线价格为1.22美元。Bright Minds Biosciences的12个月低点为0.75美元，12个月高位为8.95美元。
Institutional Inflows and Outflows
机构资金流入和流出
An institutional investor recently bought a new position in Bright Minds Biosciences stock. Jane Street Group LLC bought a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,701 shares of the company's stock, valued at approximately $37,000. Jane Street Group LLC owned 0.21% of Bright Minds Biosciences as of its most recent filing with the Securities & Exchange Commission. 4.03% of the stock is currently owned by institutional investors and hedge funds.
一家机构投资者最近买入了Bright Minds Biosciences股票的新头寸。简街集团(Jane Street Group LLC)在提交给美国证券交易委员会(Securities&Exchange Commission)的最新Form 13F文件中称，该公司在第一季度购买了Bright Minds Biosciences Inc.(纳斯达克：毒品评级)的新股份。该机构投资者买入了24,701股该公司股票，价值约37,000美元。截至最近提交给美国证券交易委员会(Securities&Exchange Commission)的文件，简街集团拥有Bright Minds Biosciences 0.21%的股份。4.03%的股票目前由机构投资者和对冲基金持有。
About Bright Minds Biosciences
关于Bright Minds生物科学
Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Bright Minds Biosciences Inc是一家临床前生物科学公司，开发5-羟色胺(5-HT)药物，以改善严重和改变生活的疾病患者的生活。该公司的选择性5-羟色胺受体激动剂组合包括5-HT2C、5-HT2A和5-HT2C/A，用于治疗癫痫、疼痛和神经精神病学。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- Can United Natural Foods Fight Both Inflation and the Fed?
- Mullen Automotive Is Ready To Get In Gear
- Cracker Barrel: A Tasty Treat Or Bad Apple?
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- 免费获取StockNews.com关于Bright Minds生物科学(药物)的研究报告
- 联合天然食品能同时对抗通胀和美联储吗？
- 马伦汽车已做好准备投入使用
- 饼干桶：可口的款待还是坏苹果？
- 防御性股票应对动荡的市场
- SunPower准备推动三位数的收益增长
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Bright Minds生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bright Minds Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。